Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy

Current Opinion in HIV and AIDS

Volumn 3, Issue 2, 2008, Pages 166-172

  Lockman, Shahin ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiretroviral treatment; Nevirapine; Prevention of mother to child transmission; Resistance

Indexed keywords

EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLACEBO; TENOFOVIR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; MOTHER CHILD RELATION; PRIORITY JOURNAL; PROPHYLAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS TRANSMISSION;

EID: 40049106667     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f50bec     Document Type: Review

References (47)

1. UNAIDS. AIDS epidemic update: special report on HIV/AIDS, December 2006. Geneva, Switzerland: UNAIDS, 2006.
2. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, April 2007. Geneva, Switzerland: World Health Organization, UNAIDS, UNICEF, 2007.
3. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
4. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-868.
5. Sripipatana T, Spensley A, Miller A, et al. Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings. Am J Obstet Gynecol 2007; 197 (3 Suppl):S107-S112.
6. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177:557-564.
7. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudinezidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083-2093.
8. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Côte d'Ivoire. J Infect Dis 2006; 193:482-487. This study shows a relatively high rate of lamivudine resistance among women exposed to short-course, non-suppressive lamivudine-containing antiretroviral regimens in Africa.
9. McIntyre J, Martinson N, Gray GE, et al. Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. In: 3rd IAS Conference. Rio de Janeiro, Brazil, 24-27 July 2005. Abstract TuFo0204.
10. Kassaye S, Lee E, Kantor R, et al. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses 2007; 23:1055-1061. This study, conducted in Zimbabwe, which is an HIV-1 subtype C-endemic area, has demonstrated the highest level of nevirapine resistance (after single-dose nevirapine exposure) among women, when standard resistance assays are used.
11. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192:30-36.
12. Sullivan J. South African Intrapartum Nevirapine Trial: Selection of resistance mutations. In: XIVth International AIDS Conference. Barcelona, Spain, 7-12 July 2002. Abstract LbPeB9024.
13. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20:1281-1288. This study, conducted among patients infected almost exclusively with subtype Cvirus, showeda relatively high prevalence, 45%, of nevirapine resistance mutations after single-dose nevirapine, despite the use of short-course zidovudine in addition to single-dose nevirapine.
14. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004, Abstract 38.
15. Chaix ML, Ekouevi DK, Peytavin G, et al. Persistence of nevirapine resistant virus and pharmacokinetic analysis in women who received intrapartum NVP associated to a short course zidovudine (ZDV) to prevent perinatal HIV-1 transmission: the Ditrame plus ANNRS 1201/02 study, Abidjan, Côte d'Ivoire [abstract 160]. Antivir Ther 2004; 9:S176.
16. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-130.
17. Jourdain G, Ngo-Giang-Huong N, Tungyai P. Exposure to intrapartum single-dose nevirapine and subsequent maternal 6-month response to NNRTI-based regimens. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004. Abstract 41LB.
18. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186:181-188.
19. Lockman S, McIntyre JA. Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine. Lancet 2007; 370:1668-1670.
20. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-2169.
21. Pillay C, Gray G, Chezzi C, et al. Nevirapine resistance mutations among HIV-1 infected infants following single-dose nevirapine. In: XVth International AIDS Conference. Bangkok, Thailand, 11-16 July 2004. Abstract WeOrB1290.
22. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007; 44:148-153. This is the largest study on the prevalence and patterns of nevirapine resistance over time among children who become HIV-infected despite the use of single-dose nevirapine to prevent MTCT.
23. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to nonnucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-1705. This study demonstrates that a single, intrapartum dose of tenofovir/emtricitabine ingested by women who have also taken short-course zidovudine and single-dose nevirapine leads to a significant reduction in the prevalence of nevirapine-resistant virus at 6 weeks postpartum, and was not associated with the development of emtricitabine/lamivudine resistance mutations. The study was not designed nor powered to determine differences in MTCT rates by tenofovir/emtricitabine receipt status. This new intervention will need to be considered for implementation.
24. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19:63-67.
25. Palombi L, Germano P, Liotta G, et al. HAART in pregnancy: safety, effectiveness, and protection from viral resistance: results from the DREAM Cohort. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005. Abstract 67.
26. Persaud D, Palumbo P, Ziemniak C, et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007; 195:1402-1410.
27. Morris L, Martinson N, Pillay C, Moodley D. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine. In: XVth International AIDS Conference. Bangkok, Thailand, 11-16 July 2004. Abstract ThOrB1353.
28. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-1573.
29. Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196:356-360.
30. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping nonnucleoside therapy. AIDS 2006; 20:701-710.
31. Shi C, Eshleman SH, Jones D, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004; 1:141-147.
32. Nissley DV, Halvas EK, Hoppman NL, et al. Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. J Clin Microbiol 2005; 43:5696-5704.
33. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43:406-413.
34. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002. This is the only published study to look for minor nevirapine-resistant variants in both maternal plasma as well as archived in maternal peripheral blood cells, over increasing time from single-dose nevirapine exposure. The prevalence of nevirapine resistance in the plasma decreased from 87% at 6 weeks to 11% at 12 months, and in cellular DNA from 52% at 6 weeks to 4% at 12 months. Archived resistance in cellular compartments (other than peripheral blood mononuclear cells) was not examined.
35. Ellis GM, Mahalanabis M, Beck IA, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 2004; 42:3670-3674.
36. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42:610-613.
37. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially under-estimated. J Infect Dis 2005; 192:16-23.
38. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-tofetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006; 103:7094-7099. This relatively small study demonstrated that standard resistance assays failed to detect resistance in the majority of women who were found to have drug-resistant strains using a highly sensitive assay.
39. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-715. This is one of the largest studies examining the persistence of nevirapine resistance mutations over a long period of time after single-dose nevirapine ingestion using highly sensitive resistance assays. This study showed that only 0.9% of women harbored low-level circulating nevirapine-resistant strains at 4 and 5 years postexposure (compared with 58.3% at 6-8 weeks postexposure).
40. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
41. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147. This is the other study to examine virological and immunologic outcomes on nevirapine-containing HAART among women in Botswana who received previous double-blind single-dose nevirapine or placebo (in addition to short-course zidovudine). Both single-dose nevirapine-exposed and unexposed women who started HAART 6 or more months postpartum had equally good virological outcomes on treatment. Single-dose nevirapine-exposed, HIV-infected infants had much higher rates of virological failure on nevirapine, zidovudine and lamivudine than non-single-dose nevirapine-exposed infants in a small number (30) of infants studied.
42. Lallemant M. Response to the therapy after prior exposure to nevirapine. In: 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005. Abstract TuFo0205.
43. Coovadia A, Marais B, Abrams E, et al. Virologic response to NNRTI treatment among women who took single-dose nevirapine 18 to 36 months earlier. In: 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA, 5-8 February 2006. Abstract 641.
44. Zijenah LS, Kadzirange G, Tobaiwa O, et al. Immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with preexposure to single dose nevirapine or short course zidovudine, in Zimbabwe. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006. Abstract 632.
45. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007; 21:957-964. This study examined CD4 cell responses to nevirapine-based HAART in the largest group of single-dose nevirapine-exposed and unexposed women to date, in a treatment programme in Zambia. CD4 cell count responses did not differ by single-dose nevirapine exposure status, although there was a trend towards worse outcomes among single-dose nevirapine-exposed women who started HAART within 6 months (versus at least 6 months) postexposure (and pretreatment CD4 cell counts were higher in the single-dose nevirapine-exposed women than in the unexposed women).
46. Bedikou G, Viho I, Tonwe-Gold B, et al. 6-Month immunological response with HAART containing nevirapine in HIV infected women post exposure to single dose of nevirapine for PMTCT. The MTCT-Plus Initiave in Abidjan, Côte d'Ivoire (2003-2005). In: 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005. Abstract MoOa0203.
47. Coffie P, Ekouevi D, Chaix ML, et al. Short-course zidovudine and lamivudine or single-dose nevirapine-containing PMTCT compromises 12-month response to HAART in African women, Abidjan, Côte d'Ivoire (2003-2006). In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007. Abstract 93LB.